Journal
INTERNATIONAL JOURNAL OF HEMATOLOGY
Volume 97, Issue 3, Pages 333-344Publisher
SPRINGER JAPAN KK
DOI: 10.1007/s12185-013-1294-z
Keywords
Multiple myeloma; Bortezomib; Lenalidomide; Thalidomide; Stem cell transplantation
Categories
Ask authors/readers for more resources
The development of novel therapeutic agents over the past decade, including the proteasome inhibitor, bortezomib, and the immunomodulatory drugs, lenalidomide and thalidomide, has resulted in improved outcomes for patients with multiple myeloma. However, there is still considerable controversy as to which regimen should be used as first-line therapy, which patients should be considered for autologous or allogeneic transplantation, and how consolidation or maintenance therapy is used in patients that have a good response to first-line therapy. The present paper will review clinical evidence from previous and ongoing studies to explore issues related to these questions.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available